How should “RET positive” NSCLC be treated?

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)250-251
Number of pages2
JournalLung Cancer
Volume108
DOIs
Publication statusPublished - 1 Jun 2017

Cite this

@article{d73e2d24cf0848a18c3f2f2eb86fc5d0,
title = "How should “RET positive” NSCLC be treated?",
author = "Smit, {Egbert F.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2017.02.006",
language = "English",
volume = "108",
pages = "250--251",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

How should “RET positive” NSCLC be treated? / Smit, Egbert F.

In: Lung Cancer, Vol. 108, 01.06.2017, p. 250-251.

Research output: Contribution to journalEditorialAcademicpeer-review

TY - JOUR

T1 - How should “RET positive” NSCLC be treated?

AU - Smit, Egbert F.

PY - 2017/6/1

Y1 - 2017/6/1

UR - http://www.scopus.com/inward/record.url?scp=85011841810&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.02.006

DO - 10.1016/j.lungcan.2017.02.006

M3 - Editorial

VL - 108

SP - 250

EP - 251

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -